Selenium-binding protein 1 transcriptionally activates p21 expression via p53-independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer

Table 1 The correlation of SELENBP1 expression with clinicopathological features in TCGA-BLCA cohort (n = 406)

Variables	SELENBP1 expression		p-value
Variables	High (n = 160)	Low (n = 246)	p-value
Age (years)
< 70	86 (40%)	128 (60%)	0.761
≥ 70	74 (39%)	118 (61%)
Sex
Female	44 (42%)	62 (58%)	0.644
Male	116 (39%)	184 (61%)
Histologic subtype
Papillary	63 (48%)	69 (52%)	0.023^a
Non-papillary	96 (36%)	173 (64%)
Missing	1 (20%)	4 (80%)
Histologic grade
Low grade	9 (43%)	12 (57%)	0.819
High grade	149 (39%)	233 (61%)
Missing	2 (67%)	1 (33%)
Primary tumor
T1/T2	56 (46%)	66 (54%)	0.090^b
T3/T4	91 (36%)	160 (64%)
Missing	13 (39%)	20 (61%)
Regional lymph node
Negative	93 (40%)	142 (60%)	0.430^c
Positive	45 (35%)	84 (65%)
Missing	22 (52%)	20 (48%)
Distant metastasis
M0	76 (39%)	120 (61%)	0.057^d
M1	1 (9%)	10 (91%)
Missing	83 (42%)	116 (58%)
Lymphovascular invasion (LVI)
Negative	59 (46%)	70 (54%)	0.469^e
Positive	62 (41%)	89 (59%)
Missing	39 (31%)	87 (69%)
TNM stage
I/II	62 (47%)	69 (53%)	0.029^f
III/IV	97 (36%)	176 (64%)
Missing	1 (50%)	1 (50%)

TCGA-BLCA The Cancer Genome Atlas bladder cancer cohort
Based on Pearson χ² test, p-value is calculated using Fisher’s exact test; Italics values denote p-value < 0.05
^aPapillary vs. non-papillary
^bT1/T2 vs. T3/T4
^cNegative vs. positive
^dM0 vs. M1
^eNegative vs. positive
^fI/II vs. III/IV

ISSN: 1479-5876